MX2019012014A - Medicina terapeutica para enfermedades fibrosas. - Google Patents

Medicina terapeutica para enfermedades fibrosas.

Info

Publication number
MX2019012014A
MX2019012014A MX2019012014A MX2019012014A MX2019012014A MX 2019012014 A MX2019012014 A MX 2019012014A MX 2019012014 A MX2019012014 A MX 2019012014A MX 2019012014 A MX2019012014 A MX 2019012014A MX 2019012014 A MX2019012014 A MX 2019012014A
Authority
MX
Mexico
Prior art keywords
peptide fragment
hmgb1 peptide
specific
inventors
present
Prior art date
Application number
MX2019012014A
Other languages
English (en)
Inventor
Tamai Katsuto
Yamazaki Takehiko
AOTO Takahiro
Yamazaki Sho
Original Assignee
Stemrim Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemrim Inc filed Critical Stemrim Inc
Publication of MX2019012014A publication Critical patent/MX2019012014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Los presentes inventores descubrieron que un péptido de fragmento de HMGB1 que tiene una secuencia de aminoácidos particular muestra efectos de inhibir la adhesión de los dedos y la cicatrización del tracto digestivo y prolonga la supervivencia en los ratones modelo con epidermólisis ampulosa distrófica. También en el modelo de úlcera de la piel, la administración del péptido de fragmento de HMGB1 específico se encontró que inhibe la fibrosidad de la piel durante el proceso de cicatrización de la úlcera. Basado en estos descubrimientos, la presente solicitud proporciona composiciones farmacéuticas para el tratamiento de enfermedades fibróticas, que comprenden el péptido de fragmento de HMGB1 específico.
MX2019012014A 2017-04-07 2018-04-06 Medicina terapeutica para enfermedades fibrosas. MX2019012014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017076600 2017-04-07
PCT/JP2018/014662 WO2018186480A1 (ja) 2017-04-07 2018-04-06 線維性疾患の治療薬

Publications (1)

Publication Number Publication Date
MX2019012014A true MX2019012014A (es) 2019-11-11

Family

ID=63713333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012014A MX2019012014A (es) 2017-04-07 2018-04-06 Medicina terapeutica para enfermedades fibrosas.

Country Status (11)

Country Link
US (1) US20200038486A1 (es)
EP (1) EP3607963A4 (es)
JP (2) JPWO2018186480A1 (es)
KR (1) KR20190135519A (es)
CN (2) CN110621331A (es)
AU (1) AU2018250076A1 (es)
BR (1) BR112019020294A2 (es)
CA (1) CA3058877A1 (es)
MX (1) MX2019012014A (es)
RU (1) RU2019134382A (es)
WO (1) WO2018186480A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805565B (zh) 2017-01-27 2023-06-21 日商斯德武利姆股份有限公司 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
EP3718561A4 (en) 2017-12-01 2021-07-21 Stemrim Inc. Therapy for inflammatory bowel disease
BR112021005982A2 (pt) * 2018-10-05 2021-06-29 StemRIM Inc. peptídeo possuindo atividade de mobilização de células-tronco mesenquimais
CN113423466A (zh) 2018-10-25 2021-09-21 国立大学法人大阪大学 软骨病症的治疗剂
JPWO2020149395A1 (ja) * 2019-01-18 2021-11-25 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
EP4144359A4 (en) * 2020-04-03 2024-05-01 Stemrim Inc PEPTIDE WITH MESENCHYMAL STEM CELL MOBILIZATION ACTIVITY
WO2023037562A1 (ja) * 2021-09-07 2023-03-16 国立大学法人大阪大学 肺炎の治療薬
WO2023053384A1 (ja) * 2021-09-30 2023-04-06 国立大学法人大阪大学 脂肪肝および非アルコール性脂肪肝炎の治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076200A2 (en) * 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
CA2778759A1 (en) * 2009-10-28 2011-05-05 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
CA2834255C (en) * 2011-04-26 2021-11-02 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
AU2013335684B2 (en) * 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
GB201508337D0 (en) * 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
TWI805565B (zh) * 2017-01-27 2023-06-21 日商斯德武利姆股份有限公司 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
CN111868231A (zh) * 2017-12-01 2020-10-30 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法

Also Published As

Publication number Publication date
CN117618534A (zh) 2024-03-01
EP3607963A4 (en) 2021-01-06
RU2019134382A3 (es) 2021-08-13
BR112019020294A2 (pt) 2020-05-12
EP3607963A1 (en) 2020-02-12
KR20190135519A (ko) 2019-12-06
JPWO2018186480A1 (ja) 2020-02-20
WO2018186480A1 (ja) 2018-10-11
AU2018250076A1 (en) 2019-10-31
US20200038486A1 (en) 2020-02-06
RU2019134382A (ru) 2021-05-07
CA3058877A1 (en) 2018-10-11
JP2023030070A (ja) 2023-03-07
CN110621331A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
MX2019012014A (es) Medicina terapeutica para enfermedades fibrosas.
MX2019012884A (es) Terapia de combinacion.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
IN2015DN00376A (es)
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
GB2496794A (en) Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract
AR103896A1 (es) Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2019011965A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
WO2016090024A3 (en) Combination therapy for treatment of cancer
MX2021002321A (es) Nuevos metodos.
BR112017009986A2 (pt) métodos para tratar indivíduos com síndrome de prader-willi ou síndrome de smith-magenis
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2021002449A (es) Vacunas peptidicas.
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
RU2015134356A (ru) Пептид
UA115250C2 (uk) Фармацевтичні комбінації
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.